Evidence map›Paper›PMID 28681704›Full record

ArticleBMC immunology2017

Experimental validation of the RATE tool for inferring HLA restrictions of T cell epitopes.

Sinu Paul, Cecilia S Lindestam Arlehamn, Veronique Schulten, Luise Westernberg, John Sidney, Bjoern Peters, Alessandro Sette

Open access · goldAbstract read
In one paragraph

Article in BMC immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 16 citations in OpenAlex.

  1. Comprehensive mapping of human CD4Cell reports. Medicine · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Peptide-Based Vaccines for Tuberculosis.Frontiers in immunology · 2022
    Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Sinu PaulDivision of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, 9420 Athena Circle, La Jolla, San Diego, CA, 92037, USA. spaul@lji.org.
Cecilia S Lindestam ArlehamnDivision of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, 9420 Athena Circle, La Jolla, San Diego, CA, 92037, USA.
Veronique SchultenDivision of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, 9420 Athena Circle, La Jolla, San Diego, CA, 92037, USA.
Luise WesternbergDivision of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, 9420 Athena Circle, La Jolla, San Diego, CA, 92037, USA.
John SidneyDivision of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, 9420 Athena Circle, La Jolla, San Diego, CA, 92037, USA.
Bjoern PetersDivision of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, 9420 Athena Circle, La Jolla, San Diego, CA, 92037, USA.
Alessandro SetteDivision of Vaccine Discovery, La Jolla Institute for Allergy and Immunology, 9420 Athena Circle, La Jolla, San Diego, CA, 92037, USA.
La Jolla Institute for Immunology · US

Funding

NIAID NIH HHS HHSN272200900042CNIAID NIH HHS HHSN272201200010CNIAID NIH HHS HHSN272201400045C
6 · The paper itself

Abstract

backgroundThe RATE tool was recently developed to computationally infer the HLA restriction of given epitopes from immune response data of HLA typed subjects without additional cumbersome experimentation.

resultsHere, RATE was validated using experimentally defined restriction data from a set of 191 tuberculosis-derived epitopes and 63 healthy individuals with MTB infection from the Western Cape Region of South Africa. Using this experimental dataset, the parameters utilized by the RATE tool to infer restriction were optimized, which included relative frequency (RF) of the subjects responding to a given epitope and expressing a given allele as compared to the general test population and the associated p-value in a Fisher's exact test. We also examined the potential for further optimization based on the predicted binding affinity of epitopes to potential restricting HLA alleles, and the absolute number of individuals expressing a given allele and responding to the specific epitope. Different statistical measures, including Matthew's correlation coefficient, accuracy, sensitivity and specificity were used to evaluate performance of RATE as a function of these criteria. Based on our results we recommend selection of HLA restrictions with cutoffs of p-value < 0.01 and RF ≥ 1.3. The usefulness of the tool was demonstrated by inferring new HLA restrictions for epitope sets where restrictions could not be experimentally determined due to lack of necessary cell lines and for an additional data set related to recognition of pollen derived epitopes from allergic patients.

conclusionsExperimental data sets were used to validate RATE tool and the parameters used by the RATE tool to infer restriction were optimized. New HLA restrictions were identified using the optimized RATE tool.

Indexed as

AllelesEpitopes, T-LymphocyteGenotyping TechniquesHistocompatibility TestingHLA AntigensFemaleHumansMaleSouth AfricaEpitopes, T-LymphocyteHLA AntigensEpitopeHLA associationHLA restrictionMHCRATET cell

Identifiers

PMID28681704
PMCPMC5499093
OpenAlexW2673684655

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.